通过治疗方案抑制肿瘤微环境中的免疫应答可以阻碍肿瘤的根除,可能导致肿瘤转移。作为一种非侵入性的治疗方法,放射治疗用于肿瘤消融。在这项研究中,我们的目的是提高放疗的治疗效果和触发免疫反应,通过制定一个苯并噻唑(BTS)-亚磺酸酯(BTS)-负载融合脂质体(BFL)纳米平台,然后与放疗相结合进行抗癌治疗。血小板细胞膜,配备独特的表面受体,使BFL能够有效地靶向肿瘤,同时逃避免疫系统并粘附于肿瘤细胞。这有助于BFL被癌细胞吞噬,随后释放其中的BTS。发布后,BTS生产二氧化硫(SO2)用于气体治疗,启动细胞内谷胱甘肽(GSH)的氧化。这个过程证明了在放射治疗后修复损伤的有效性,从而实现有效的放射增敏。揭示了在BFL促进的增强的放射增敏作用后触发了免疫应答。这种方法促进了淋巴结内树突状细胞(DC)的成熟,导致远端肿瘤中T细胞比例增加。这导致原发性肿瘤的显著根除和远处肿瘤生长的抑制。总之,个性化BFL与放疗的整合显示出增强肿瘤免疫反应和消除肿瘤的潜力,包括转移。
The inhibition of the immune response in the tumor microenvironment by therapy regimens can impede the eradication of tumors, potentially resulting in tumor metastasis. As a non-invasive therapeutic method,
radiotherapy is utilized for tumor ablation. In this study, we aimed to improve the therapeutic impact of
radiotherapy and trigger an immune response by formulating a benzothiazole sulfinate (BTS)-loaded fusion liposome (BFL) nanoplatform, which was then combined with
radiotherapy for anti-cancer treatment. The platelet cell membrane, equipped with distinctive surface receptors, enables BFL to effectively target tumors while evading the immune system and adhering to tumor cells. This facilitates BFL\'s engulfment by cancer cells, subsequently releasing BTS within them. Following the release, the BTS produces sulfur dioxide (SO2) for gas therapy, initiating the oxidation of intracellular glutathione (GSH). This process demonstrates efficacy in repairing damage post-
radiotherapy, thereby achieving effective radiosensitization. It was revealed that an immune response was triggered following the enhanced radiosensitization facilitated by BFL. This approach facilitated the maturation of dendritic cell (DC) within lymph nodes, leading to an increase in the proportion of T cells in distant tumors. This resulted in significant eradication of primary tumors and inhibition of growth in distant tumors. In summary, the integration of personalized BFL with
radiotherapy shows potential in enhancing both tumor immune response and the elimination of tumors, including metastasis.